Search

Your search keyword '"Luka, Janos"' showing total 115 results
Start Over Author "Luka, Janos"
115 results on '"Luka, Janos"'

14. Development of a serum biomarker assay that differentiates tumor-associated MUC5AC (NPC-1C ANTIGEN) from normal MUC5AC

Author

Luka, Janos, Arlen, Philip M., and Bristol, Andrew

Subjects
Diagnosis, Care and treatment, Physiological aspects, Usage, Development and progression, Research, Antigens -- Physiological aspects -- Research, Enzyme-linked immunosorbent assay -- Usage, Pancreatic cancer -- Development and progression -- Diagnosis -- Care and treatment -- Research, Biological markers -- Research
Abstract

1. Introduction The early diagnosis of colorectal and pancreatic cancers remains an area of high unmet medical need, as underscored by the U S estimated combined, annual death rate of [...], A serum ELISA using a monoclonal antibody that detects a MUC5AC-related antigen (NPC-1C antigen) expressed by pancreatic and colorectal cancer was developed. The NPC-1C antibody reacts with specific epitopes expressed by tumor-associated MUC5AC that does not appear on MUC5AC from normal tissues. Based on observations of a highly specific antibody, we tested the ELISA to differentiate serum from healthy blood donors compared to serum from patients with colorectal or pancreatic cancer. Additionally, patient tumor tissue was stained to examine the expression pattern of MUC5AC-related antigen in pancreatic and colorectal cancers. The results indicate the NPC-1C antibody ELISA distinguished serum of cancer patients from normal donors with very good sensitivity and specificity. Most patient's tumor biopsy exhibited NPC-1C antibody reactivity, indicating that tumor-associated MUC5AC antigen from tumor is shed into blood, where it can be detected by the NPC-1C antibody ELISA. This serum test provides a new tool to aid in the diagnosis of these cancers and immune monitoring of cancer treatment regimens.

Published
2011
Full Text
View/download PDF

24. Multicenter evaluation of PCR methods fordetecting CMV DNA in blood donors

Author

Roback, John D., primary, Hillyer, Christopher D., additional, Drew, W. Lawrence, additional, Laycock, Megan E., additional, Luka, Janos, additional, Mocarski, Edward S., additional, Slobedman, Barry, additional, Smith, James W., additional, Soderberg-Naucler, Cecilia, additional, Todd, Deborah S., additional, Woxenius, Susanne, additional, and Busch, Michael P., additional

Published
2001
Full Text
View/download PDF

35. Detection of Antigens Associated With Epstein-Barr Virus Replication in Extracts From Biopsy Specimens of Nasopharyngeal Carcinomas2.

Author

Luka, Janos, Deeb, Ziad E., Hartmann, Dan P., Jenson, Bennett, and Pearson, Gary R.

Abstract

By using monoclonal antibodies to different Epstein-Barr virus (EBV) polypeptides in combination with immunoblotting, we detected antigens associated with EBV replication in extracts from nasopharyngeal carcinoma (NPC) biopsy specimens. Major polypeptides associated with both the diffuse and the restricted components of the early antigen (EA) complex were found in extracts from nine of nine of nine NPC biopsy specimen, passaged repeatedly in nude mice, were found to positive for the major EA (restricted) polypeptide. This approach revealed that extracts from three of 14 biopsy specimens from other benign and malignant diseases also expressed these viral ploypeptides. Therefore, for the first time, these results conclusively demonstrate the presence of EA polyypeptides in extracts from NPC biopsy specimens. This finding provides at least a partial explanation for the reported prognostic value of antibodies to this antigen in patients with this disease. [J Natl Cancer Inst 1988;80:1164–1167] [ABSTRACT FROM PUBLISHER]

Published
1988

39. Immunochemical Characterization of Epstein-Barr Virus-Associated Early and Late Antigens in n-Butyrate-Treated P3HR-1 Cells

Author

Kallin, Bengt, Luka, Janos, and Klein, George

Abstract

Sodium butyrate induces the Epstein-Barr virus cycle in latently infected P3HR-1 cells with a high efficiency. This fact was utilized for the metabolic labeling of the Epstein-Barr virus antigens. Nonproducer Raji cells, lacking both early antigen and viral capsid antigen, were used as controls. Immunoprecipitation patterns were compared with 13 anti-Epstein-Barr virus (viral capsid antigen) - positive and 3 negative sera. Sixteen polypeptides were identified as being associated with the lytic Epstein-Barr virus cycle. Their molecular weights ranged from 31,000 (31K) to 275K on sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Two polypeptides, 158K and 165K, could be classified as late viral products on the basis of their sensitivity to cytosine arabinoside. Six of the polypeptides, i.e., 90K, 95K, 134K, 165K, 236K, and 275K, were detected by [3H]glucosamine labeling. Among the early, cytosine arabinoside-insensitive polypeptides detected by [35S]methionine labeling, a 152K component appears to be a major constituent of early antigen. This polypeptide was precipitated by all anti-Epstein-Barr virus-positive sera tested. As a rule, together with the 103K and 134K polypeptides, the 152K component is precipitated by anti-early antigen, R (restricted) antibodies. In addition, anti-early antigen D (diffuse) antibodies precipitate 31K, 51K, 65K, and 90K components.

Published
1979
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results